3-MeO-PCMo
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by InternetArchiveBot (talk | contribs) at 03:18, 5 June 2020 (Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.1). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:18, 5 June 2020 by InternetArchiveBot (talk | contribs) (Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.1)
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H25NO2 |
| Molar mass | 275.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-MeO-PCMo is a dissociative anesthetic drug which is similar in structure to phencyclidine[1][2] and been sold online as a designer drug.[3][4] The inhibitory effect of 3-MeO-PCMo on the reduction in the density of the drebrin clusters by NMDAR stimulation with glutamate acid is lower than that of PCP or 3-MeO-PCP, with IC50 values of 26.67 μM (3-MeO-PCMo), 2.02 μM (PCP) and 1.51 μM (3-MeO-PCP).[5]
See also
References
- ^ Ahmadi, Abbas; Khalili, Mohsen; Hajikhani, Ramin; Naserbakht, Moslem (April 2011). "New morpholine analogues of phencyclidine: Chemical synthesis and pain perception in rats". Pharmacology Biochemistry and Behavior. 98 (2): 227–233. doi:10.1016/j.pbb.2010.12.019. ISSN 0091-3057. PMID 21215770.
- ^ Abiero, Arvie; Botanas, Chrislean Jun; Custodio, Raly James; Sayson, Leandro Val; Kim, Mikyung; Lee, Hyun Jun; Kim, Hee Jin; Lee, Kun Won; Jeong, Youngdo; Seo, Joung-Wook; Ryu, In Soo; Lee, Yong Sup; Cheong, Jae Hoon (December 2019). "4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels". Psychopharmacology. doi:10.1007/s00213-019-05412-y. ISSN 1432-2072. PMID 31828394.
- ^ Colestock, Tristan; Wallach, Jason; Mansi, Matt; Filemban, Nadine; Morris, Hamilton; Elliott, Simon P.; Westphal, Folker; Brandt, Simon D.; Adejare, Adeboye (February 2018). "Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues". Drug Testing and Analysis. 10 (2): 272–283. doi:10.1002/dta.2213. ISSN 1942-7611. PMID 28513099.
- ^ "3-MeO-PCMo". New Synthetic Drugs Database. Archived from the original on 2016-07-03. Retrieved 2016-02-09.
- ^ Mitsuoka, Toshinari; Hanamura, Kenji; Koganezawa, Noriko; Kikura-Hanajiri, Ruri; Sekino, Yuko; Shirao, Tomoaki (September–October 2019). "Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay". Journal of Pharmacological and Toxicological Methods. 99: 106583. doi:10.1016/j.vascn.2019.106583. ISSN 1056-8719. PMID 31082488.
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
|---|---|
| KARTooltip Kainate receptor |
|
| NMDARTooltip N-Methyl-D-aspartate receptor |
|
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |